Browse by author
Lookup NU author(s): Dr Karen Wallace,
Professor Matthew Wright
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Chronic liver disease results in a liver-scarring response termed fibrosis. Excessive scarring leads to cirrhosis, which is associated with high morbidity and mortality. The only treatment for liver cirrhosis is liver transplantation; therefore, much attention has been directed toward therapies that will slow or reverse fibrosis. Although anti-fibrogenic therapies have been shown to be effective in experimental animal models, licensed therapies have yet to emerge. A potential problem for any anti-fibrogenic therapy in the liver is the existence of the body's major drug metabolising cell (the hepatocyte) adjacent to the primary fibrosis-causing cell, the myofibroblast. This article reviews the development of a human recombinant single-chain antibody (scAb) that binds to the surface of myofibroblasts. This antibody binds specifically to myofibroblasts in fibrotic mouse livers. When conjugated with a compound that stimulates myofibroblast apoptosis, the antibody directs the specific apoptosis of myofibroblasts with greater specificity and efficacy than the free compound. The antibody also reduces the adverse effect of liver macrophage apoptosis and-in contrast to the free compound-reversed fibrosis in the sustained injury model used. These data suggest that specifically stimulating the apoptosis of liver myofibroblasts using a targeting antibody has potential in the treatment of liver fibrosis. © 2008 Asian Pacific Association for the Study of the Liver.
Author(s): Douglass A, Wallace K, Koruth M, Barelle C, Porter AJ, Wright MC
Publication type: Article
Publication status: Published
Journal: Hepatology International
ISSN (print): 1936-0533
ISSN (electronic): 1936-0541
Altmetrics provided by Altmetric